---
title: "Mural Oncology (MURA.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/MURA.US.md"
symbol: "MURA.US"
name: "Mural Oncology"
industry: "Biotechnology"
---

# Mural Oncology (MURA.US)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |

## Company Profile

Mural Oncology plc operates as a clinical-stage oncology company that focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company’s lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-re...

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.30 | 112/603 | - | - | - |
| PB | 0.64 | 46/603 | 0.64 | 0.61 | 0.38 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2025-10-09T04:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 0 | 0% |
| Overweight | 0 | 0% |
| Hold | 1 | 100% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 2.04 |
| Highest Target | 6.00 |
| Lowest Target | 6.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/MURA.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/MURA.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/MURA.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.